PRESS RELEASES

Date Title and Summary View
Oct 4, 2018
Summary ToggleZafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference
Nonclinical data for ZGN-1258 reproduce efficacy seen in first generation candidate for PWS Data show highly improved safety profile Company also presenting study design of PATH for PWS natural history study co-sponsored by FPWR BOSTON , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Zafgen ,
Summary ToggleZafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference
Aug 8, 2018
Summary ToggleZafgen to Present at the Wedbush PacGrow Healthcare Conference

BOSTON , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield

Summary ToggleZafgen to Present at the Wedbush PacGrow Healthcare Conference
Aug 7, 2018
Summary ToggleZafgen Reports Second Quarter 2018 Operating and Financial Results

Phase 1 clinical trial for ZGN-1258 for Prader-Willi syndrome (PWS) expected to begin in the fourth quarter 2018 Multiple ZGN-1258 nonclinical studies accepted for presentation at upcoming Foundation for Prader-Willi Research (FPWR) Annual Conference Initiated 1.8 mg dosing arm in ZGN-1061 Phase 2

Summary ToggleZafgen Reports Second Quarter 2018 Operating and Financial Results
Aug 2, 2018
Summary ToggleZafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes

BOSTON , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today that Thomas Hughes , Ph.D., has resigned from his

Summary ToggleZafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes
Aug 1, 2018
Summary ToggleZafgen to Present at the Canaccord Genuity 38th Annual Growth Conference

BOSTON , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield

Summary ToggleZafgen to Present at the Canaccord Genuity 38th Annual Growth Conference
Jul 31, 2018
Summary ToggleZafgen to Host Conference Call to Discuss Second Quarter 2018 Financial Results

BOSTON , July 31, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a

Summary ToggleZafgen to Host Conference Call to Discuss Second Quarter 2018 Financial Results
Jul 9, 2018
Summary ToggleZafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study

Information and data from study will advance understanding of medical history and medical events in people with PWS People living with PWS ages 5 and older and their caregivers are encouraged to participate BOSTON, July 09, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc.

Summary ToggleZafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study
Jul 2, 2018
Summary ToggleZafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares

BOSTON , July 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced the closing of its previously

Summary ToggleZafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares
Jun 28, 2018
Summary ToggleZafgen Announces Pricing of Offering of Common Stock

BOSTON , June 28, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced the pricing of its previously

Summary ToggleZafgen Announces Pricing of Offering of Common Stock
Jun 27, 2018
Summary ToggleZafgen Announces Proposed Offering of Common Stock

BOSTON , June 27, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced that it has commenced an

Summary ToggleZafgen Announces Proposed Offering of Common Stock